Bio-Rad Laboratories news

Mixed outlook with positive tailwinds (quality control/blood typing growth, international diversification) offset by significant headwinds (China decline, FX pressure, geopolitical costs). Zacks Rank #3 (Hold) reflects balanced risk-reward with modest 2.6% segment growth but constrained full-year guidance.

Activist involvement and identification of hidden value (Sartorius stake worth ~$5B) suggest potential for strategic improvements and shareholder value creation. Stock rallied 12.94% on the news, indicating market optimism about potential changes.

Established market participant with transfection reagent offerings; benefits from market growth but no specific recent developments or competitive advantages highlighted.

Listed as key player in immunology and serology testing segment, which captured 24% market share in 2025 and benefits from routine health checks and disease diagnosis demand.

Identified as a market participant in the growing TDM consumables sector, positioned to benefit from increased demand for quality consumables and standardized workflows.

Listed as a notable metabolomics market participant with opportunities in a market projected to grow at 12.36% CAGR through 2035.

Featured company in the magnetic bead purification kits market with exposure to biotechnology and diagnostic laboratory end-users.

Listed among leading companies in the moderately concentrated market, positioned to benefit from growing demand for kits, reagents, and instruments in epigenetics research.

Identified as a principal competitive player in the growing multiplex assays market, well-positioned to capture market share as the industry expands at double-digit growth rates.

Bio-Rad is listed as a key player in the blood-based biomarkers market with involvement in diagnostic solutions.

Invested $295.9 million in R&D in 2024, signaling commitment to AI-integrated future and positioning within evolving bioinformatics landscape.

Listed as a leading player with transfusion diagnostic systems (BioPlex 2200, Bio-Rad Transfusion Diagnostic Systems) benefiting from market expansion.

Identified as a leading market player in the growing molecular biology enzymes, reagents and kits sector.

Identified as a dominant North American player with recent innovation (Bio-Plex Cell Signaling Assays launched in 2024), positioning the company well to capitalize on the expanding oxidative stress assay market.

Listed as a key market player in the growing laboratory equipment services market, benefiting from increased demand for diagnostic and life science equipment support services.

Up 9-13% premarket on Elliott Investment Management stake disclosure. Activist involvement provides catalyst for cost discipline, divestitures, and buybacks; stock trades at wide discount to sum-of-parts.

Listed among major companies in the cancer biomarkers market, which is projected to grow significantly through 2031 driven by precision oncology adoption and companion diagnostics expansion.

Identified as a key player in the expanding DNA microarray market, well-positioned to capture growth from increasing demand for genomic research and personalized medicine applications.

Included as a key player in the growing targeted sequencing market, benefiting from increased adoption in research and clinical applications.

Dropped 10.6% after cutting 2026 revenue and margin outlook

Key player in the drug screening market with exposure to growing demand for immunoassay and chromatography technologies, which held 44.77% market share in 2025.

Included as a key market participant in a growing industry driven by technological advancements and increased adoption in clinical settings.